Literature DB >> 16513327

Induction of apoptosis by paclitaxel in human oral carcinoma cells.

M Nonaka1, H Ikeda, A Fujisawa, M Uehara, T Inokuchi.   

Abstract

The present study investigated induction of apoptosis in NB-1 oral carcinoma cells by paclitaxel and the expression of Bcl-2 and Bax in relation to this apoptotic cell death. Paclitaxel induced apoptotic cell death in NB-1 cells in a dose- and a time-dependent manner. The present results suggest that paclitaxel can induce apoptosis of NB-1 cells, which may be mediated by down-regulation of Bcl-2 together with up-regulation of Bax.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513327     DOI: 10.1016/j.ijom.2006.01.011

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  4 in total

1.  Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.

Authors:  Daisuke Sano; David R Fooshee; Mei Zhao; Genevieve A Andrews; Mitchell J Frederick; Chad Galer; Zvonimir L Milas; Phuong Khanh H Morrow; Jeffrey N Myers
Journal:  Head Neck       Date:  2011-03       Impact factor: 3.147

2.  Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells.

Authors:  Xiaoli Ren; Bingbing Zhao; Hongjian Chang; Min Xiao; Yuhong Wu; Yun Liu
Journal:  Mol Med Rep       Date:  2018-04-11       Impact factor: 2.952

3.  Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model.

Authors:  Juan Riestra-Ayora; Carolina Sánchez-Rodríguez; Raquel Palao-Suay; Joaquín Yanes-Díaz; Ana Martín-Hita; María Rosa Aguilar; Ricardo Sanz-Fernández
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

4.  An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.

Authors:  In Hae Park; Joo Hyuk Sohn; Sung Bae Kim; Keun Seok Lee; Joo Seop Chung; Soo Hyeon Lee; Tae You Kim; Kyung Hae Jung; Eun Kyung Cho; Yang Soo Kim; Hong Suk Song; Jae Hong Seo; Hun Mo Ryoo; Sun Ah Lee; So Young Yoon; Chul Soo Kim; Yong Tai Kim; Si Young Kim; Mi Ryung Jin; Jungsil Ro
Journal:  Cancer Res Treat       Date:  2016-09-12       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.